STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma
Publication in refereed journal


Times Cited
Altmetrics Information
.

Other information
AbstractHepatocellular carcinoma (HCC) is a major global health problem and its treatment options have been limited. Signal transducer and activator of transcription 3 (STAT3) is a transcription factor important for various cellular processes. Overexpression and constitutive activation of STAT3 have been frequently found in HCC and associated with poor prognosis. Ample evidence has shown that STAT3 plays pivotal roles in the initiation, progression, metastasis and immune suppression of HCC. Thus, STAT3 has attracted attention as a novel therapeutic target in HCC. Clinical trials have investigated STAT3-targeted therapeutics either as monotherapy or in combination with chemotherapeutic agents, immune checkpoint inhibitors and alternative targeted drugs. Some of these studies have yielded encouraging results. Particularly, napabucasin—a cancer stemness inhibitor targeting STAT3-driven gene transcription—has stood out with its promising clinical efficacy and safety profile. Nonetheless, clinical investigations of STAT3-targeted therapies in HCC are limited and more efforts are strongly urged to evaluate their clinical performance in HCC. Here, we provide a comprehensive review of the roles of STAT3 in HCC and follow by comprehensive analysis of STAT3 targeted strategies.
All Author(s) ListLee C, Cheung ST
Journal nameCancers
Year2019
Month11
Volume Number11
Issue Number11
PublisherMDPI
Article number1646
ISSN2072-6694
LanguagesEnglish-United Kingdom
KeywordsSTAT3, transcription factor, targeted therapy, combination therapy, hepatocellular carcinoma
Web of Science Subject CategoriesOncology;Oncology

Last updated on 2020-19-10 at 01:30